Summary:
A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matched-sibling donor. The patient's pre- and post transplant course were complicated by an autoimmune disorder and her post transplant course was complicated by severe hepatic and gastrointestinal GVHD. A technetium-99m sulfur colloid scan 4 months post transplant and bone marrow studies 8 months post transplant demonstrated intramedullary hematopoiesis, complete resolution of marrow fibrosis, and partial resolution of osteosclerosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tefferi A . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265.
Smith BD, Moliterno A . Biology and management of idiopathic myelofibrosis. Curr Opin Oncol 2001; 13: 91–94.
Anderson JE, Tefferi A, Craig F et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 2001; 98: 586–593.
Guardiola P, Anderson JE, Bandini G et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European group for blood and marrow transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Modello Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831–2838.
Ramakrishna R, Kyle PW, Day PJ, Manoharan A . Evans' syndrome, myelofibrosis, and systemic lupus erythematosus: role of procollagens in myelofibrosis. Pathology 1995; 27: 255–259.
Paquette R, Meshkinpour A, Rosen P . Autoimmune myelofibrosis: a steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Medicine 1994; 73: 145–152.
Maris M . Nonmyeloablative allogeneic hematopoietic stem cell transplantation. Fellow Reporter 2001; 6: 59–62.
Cervantes F, Barosi G, Demory JL et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors, and identification of risk groups. Br J Haematol 1998; 102: 684–690.
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.
Tefferi A, Messa RA, Nagorney DM et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226–2233.
Li Z, Deeg HJ . Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation. Leukemia 2001; 15: 465–467.
Coates GG, Eisenberg B, Dail DH . Tc-99m sulfur colloid demonstration of diffuse pulmonary interstitial extra medullary hematopoiesis in a patient with myelofibrosis: a case report and review of the literature. Clin Nucl Med 1994; 19: 1079–1084.
Kucuk O, Gordon LI, Kies MS et al. Estimation of hematopoietic potential by CFU-c and bone marrow scan in cancer patients. Exp Hematol 1984; 12: 101–106.
Derin H, Yetkin E, Ozkilic H et al. Detection of splenosis by radionuclide scanning. Br J Radiol 1987; 60: 873–875.
Dumarey N, Martin P, Jayankura M et al. A ‘made in one piece’ skeleton in a 22-year-old man suffering from sickle cell anaemia. Clin Rheumatol 2000; 19: 287–290.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tanner, M., Hoh, C., Bashey, A. et al. FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia. Bone Marrow Transplant 32, 581–585 (2003). https://doi.org/10.1038/sj.bmt.1704172
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704172
Keywords
This article is cited by
-
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?
Bone Marrow Transplantation (2015)
-
Choosing between stem cell therapy and drugs in myelofibrosis
Leukemia (2008)
-
Allogeneic stem cell transplantation as treatment for myelofibrosis
Bone Marrow Transplantation (2006)
-
Outcome of allogeneic stem cell transplantation in patients with myelofibrosis
Bone Marrow Transplantation (2004)